City of Hope | Strategic Alliance Partners

Afsaneh Barzi, MD, PhD, discusses challenges treating oncologists face when aiming to navigate the treatment landscape of patients with gastroesophageal cancers and highlights the evolution of treatments for patients with these diseases.

Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.

City of Hope announced the appointment of Marcel van den Brink, MD, PhD, as president of City of Hope Los Angeles and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair in honor of Alexandra Levine, MD.

Swetha Kambhampati, MD, discusses how findings from a subgroup analysis of investigating the use of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma may support the continued exploration of this agent in earlier lines of therapy.

In this first episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss how endoscopic ultrasound has changed the diagnosis of pancreatic cancer and how it may also be utilized to guide personalized treatment in nonmetastatic adenocarcinomas.

Marwan G. Fakih, MD, discusses the main objective and design of the observational BASECAMP-1 study and how it functions alongside the phase 1/2 EVEREST-1 study in patients with solid tumors.

Researchers at City of Hope were awarded $32.3 million from the CIRM to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia.

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

Several articles featured in a recent issue of the highly respected publication the Medical Letter on Drugs and Therapeutics highlight themes across drug development that are relevant within the broad antineoplastic arena. The topics range from appropriate control arms in randomized clinical trials to sponsorship of trials to the rationale for developing novel agents when suitable, cost-effective biosimilar and generic products are available.

The ranking by U.S. News & World Report marks the latest recognition for the organization as one of the nation’s elite cancer hospitals.

Erminia Massarelli MD, PhD, MS, discusses strategies created by City of Hope to effectively navigate the treatment of patients with lung cancer during the platinum chemotherapy shortage in the United States.

Edward S. Kim, MD, MBA, discusses drug shortages in cancer care, detailing how City of Hope has continued to establish efforts to mitigate the effects of these shortages.

Erminia Massarelli MD, PhD, MS, discusses efficacy and safety data with the NTRK inhibitors larotrectinib and entrectinib in patients with non–small cell lung cancer harboring NTRK fusions.

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

Alexey Danilov, MD, PhD, reviews data from the phase 2 TRANSCEND FL trial investigating lisocabtagene maraleucel and discusses the clinical implications of the results.

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.

In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.

ASCO has released an update to the guidelines for the practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy.

Marwan G. Fakih, MD, reviews data from the phase 3 randomized SUNLIGHT trial investigating trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer.

Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.

An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes.

Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.

In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.

Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.

Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.

Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert and dives into the unique mechanism of action of A2B530.

In this fifth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, walk through the key lessons learned from the prospective, multicenter PATHINDER study (NCT04241796), which evaluated a multicancer early detection test developed by GRAIL.